CN114591338B - Preparation method and application of Syk and VEGFR2 double-target inhibitor - Google Patents
Preparation method and application of Syk and VEGFR2 double-target inhibitor Download PDFInfo
- Publication number
- CN114591338B CN114591338B CN202210343193.5A CN202210343193A CN114591338B CN 114591338 B CN114591338 B CN 114591338B CN 202210343193 A CN202210343193 A CN 202210343193A CN 114591338 B CN114591338 B CN 114591338B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- group
- reaction
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 title abstract description 18
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 title abstract description 16
- 239000003112 inhibitor Substances 0.000 title abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 92
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 238000006243 chemical reaction Methods 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 32
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 14
- 229910052763 palladium Inorganic materials 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 230000003197 catalytic effect Effects 0.000 claims description 9
- 229910052731 fluorine Inorganic materials 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 239000003054 catalyst Substances 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 229910052740 iodine Inorganic materials 0.000 claims description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 238000010511 deprotection reaction Methods 0.000 claims description 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 5
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 claims description 3
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000003566 oxetanyl group Chemical group 0.000 claims description 2
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 claims description 2
- 235000019439 ethyl acetate Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 20
- 230000003287 optical effect Effects 0.000 abstract description 10
- 238000006069 Suzuki reaction reaction Methods 0.000 abstract description 9
- ZPQVSAYWOQAEMZ-UHFFFAOYSA-N boric acid;1h-pyrazole Chemical class OB(O)O.C=1C=NNC=1 ZPQVSAYWOQAEMZ-UHFFFAOYSA-N 0.000 abstract description 7
- 239000002207 metabolite Substances 0.000 abstract description 7
- 239000000651 prodrug Substances 0.000 abstract description 7
- 229940002612 prodrug Drugs 0.000 abstract description 7
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000009977 dual effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 238000003756 stirring Methods 0.000 description 18
- 201000010099 disease Diseases 0.000 description 15
- -1 Boc-protected pyrazole boronates Chemical class 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000012065 filter cake Substances 0.000 description 11
- 239000002994 raw material Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 238000001291 vacuum drying Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 description 5
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 4
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 4
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 4
- 206010064930 age-related macular degeneration Diseases 0.000 description 4
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 208000002780 macular degeneration Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 230000007783 downstream signaling Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000008299 semisolid dosage form Substances 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 description 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-L D-glucarate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O DSLZVSRJTYRBFB-LLEIAEIESA-L 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 101000742596 Homo sapiens Vascular endothelial growth factor C Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000022120 Jeavons syndrome Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000000551 Syk Kinase Human genes 0.000 description 1
- 108010016672 Syk Kinase Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000008228 bacteriostatic water for injection Substances 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 229920002678 cellulose Chemical class 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical compound [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- YWWARDMVSMPOLR-UHFFFAOYSA-M oxolane;tetrabutylazanium;fluoride Chemical compound [F-].C1CCOC1.CCCC[N+](CCCC)(CCCC)CCCC YWWARDMVSMPOLR-UHFFFAOYSA-M 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The application relates to a preparation method and application of a Syk and VEGFR2 double-target inhibitor. In particular, the present application relates to a process for preparing a compound of formula (I) or an isotopically-labelled compound thereof, or an optical isomer, a geometric isomer, a tautomer or a mixture of isomers, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof, which does not require preferential protection of pyrazole borates and which is capable of proceeding smoothly with the subsequent Suzuki reaction for the preparation of Syk and VEGFR2 dual target inhibitors.
Description
Technical Field
The application belongs to the field of medicine synthesis, and particularly relates to a preparation method and application of a spleen tyrosine kinase (Syk) and vascular endothelial growth factor 2 (VEGFR 2) double-target inhibitor.
Background
Syk is a non-receptor tyrosine kinase that plays an important role in immunoreceptor-mediated and integrin-mediated signal transduction in a variety of cell types, including B cells, macrophages, monocytes, mast cells, eosinophils, basophils, neutrophils, dendritic cells, T cells, natural killer cells, platelets and osteoclasts. The immunoreceptors described in this application include typical immunoreceptors and immunoreceptor-like molecules. Typical immunoreceptors include B-cell and T-cell antigen receptors and a variety of immunoglobulin receptors (Fc receptors). Immunoreceptor-like molecules are structurally related to immunoreceptors or participate in similar signaling pathways, and are primarily involved in non-adaptive immune functions (including neutrophil activation, natural killer cell recognition, and osteoclast activity). Integrins are cell surface receptors that play a critical role in leukocyte adhesion and activation of both innate and acquired immunity.
VEGFR2, also known as KDR or Flk-1, is identified as a receptor for VEGF and VEGFC, an early marker of endothelial cell progenitors, whose expression is restricted to endothelial cells in vivo. VEGFR2 has been shown to be the primary signal transducer for angiogenesis and the development of pathological conditions such as cancer and diabetic retinopathy. Studies have shown that anti-VEGF can exert an inhibitory effect on the expression and activation of pro-inflammatory factors, thereby reducing ocular surface inflammation. VEGFR2 transduces the primary signal of angiogenesis through its potent tyrosine kinase activity. However, unlike other representative tyrosine kinase receptors, VEGFR2 does not use the Ras pathway as the primary downstream signaling, but uses the phospholipase C protein kinase C pathway to express Mitogen Activated Protein (MAP) kinase activation and DNA synthesis. Therefore, inhibition of VEGFR2 activity and its downstream signaling is an important target for the treatment of diseases involving angiogenesis, inflammation, etc.
Thus, inhibition of Syk and VEGFR-2 activity is useful in the treatment of allergic, autoimmune and inflammatory diseases including, but not limited to, dry eye and allergic conjunctivitis, retinal inflammatory diseases, age-related macular degeneration (AMD), proliferative Diabetic Retinopathy (PDR) and retinopathy of prematurity (ROP), cancer, rheumatoid arthritis, glomerulonephritis, multiple vasculitis, idiopathic Thrombocytopenic Purpura (ITP), myasthenia gravis, allergic rhinitis, chronic Obstructive Pulmonary Disease (COPD), adult respiratory distress syndrome (ARD), asthma, and the like.
PCT international patent application WO2021169958A1, entitled "1H-pyrazole derivatives and uses as dual-target inhibitors of Syk and VEGFR 2", discloses a dual-target inhibitor for Syk and VEGFR2, and further discloses various methods of preparing such dual-target inhibitors, including, for example:
the preparation method 1 comprises the following steps:
the preparation method 2 comprises the following steps:
in the Suzuki coupling reaction of the PCT International patent application, the palladium catalyst system adopted is Pd (dppf) Cl 2 A catalytic system that is a precursor; in order to ensure the reactivity of the palladium catalyst system in the Suzuki reaction, the pyrazole borate needs to be protected by adopting a Boc or SEM group to prevent complexation with the catalyst; after the coupling reaction is completed, the protecting group Boc or SEM is removed under the corresponding conditions to give crude compounds 1-6. In this process, the Boc-protected pyrazole boronates require additional column chromatography purification to prevent the byproduct residues in the reaction of the upper protecting group from affecting the catalytic system activity of the Suzuki reaction.
Thus, a method is being sought that does not require preferential protection of pyrazole borates and that can successfully proceed with subsequent Suzuki reactions to produce Syk and VEGFR2 dual-target inhibitors.
Disclosure of Invention
The invention aims to overcome the defect that the existing method for preparing the Syk and VEGFR2 double-target inhibitor needs to protect pyrazole borate serving as a reaction raw material to prevent complexation with a catalyst and also needs an additional specific step to remove a protecting group, and provides a method which does not need to protect the pyrazole borate preferentially and can smoothly carry out subsequent Suzuki reaction to prepare the Syk and VEGFR2 double-target inhibitor.
In a first aspect, the present application provides a process for the preparation of a compound of formula (I) or an isotopically-labelled compound thereof, or an optical isomer, geometric isomer, tautomer or mixture of isomers, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof,
wherein,,
R 1 and R is 2 One of which is H and the other of which is pyrazolyl;
R 3 and R is 4 Each independently selected from the group consisting of H, F, cl, br, I, OH, NH 2 、CN、C 1-3 Alkyl and C 1-3 Alkoxy group, said C 1-3 Alkyl and C 1-3 Alkoxy is optionally substituted with 1, 2 or 3 halogens;
T 1 CH or N;
R 5 and R is 6 Each independently selected from the group consisting of H, F, cl, br, I, OH and C 1-3 Alkyl group, said C 1-3 Alkyl is optionally substituted with 1, 2 or 3 halogens; alternatively, R 5 And R is 6 Together with the carbon atoms to which they are attached form an oxetanyl group;
R 8 is H or-C (=O) -C 1-3 An alkyl group; and
n is 1 or 2; and is also provided with
Wherein the method comprises the steps of:
reacting a compound of formula (II):
wherein,,
R 9 and R is 10 One of which is H and the other is halogen;
with a compound of formula (III):
the reaction is carried out,
and after the reaction is finished, adding a deprotection agent into a reaction system to remove a protected SEM group so as to obtain the compound of the formula (I).
In the method, unprotected pyrazole borate is adopted in the Suzuki reaction, and SEM-Cl is selected as a ligand; unprotected pyrazole groups have no influence on the activity of the palladium catalytic system, and the Suzuki reaction can be smoothly carried out; the unprotected pyrazole borate is used for Suzuki reaction, and then a deprotection agent is directly added into a reaction system to directly generate a crude product of the compound shown in the formula (I), namely, the synthesis is completed in one reaction system without transfer.
In addition, the reactant compounds of the present application (e.g., compounds of formula (II) or (III)) may be prepared in a variety of ways known to those skilled in the art of organic synthesis, for example, as described in PCT international patent application WO2021169958A1 by the applicant. In addition, those skilled in the art can refer to the synthetic routes of the specific compounds of the specific examples of the present application, and appropriately adjust the reaction raw materials and reaction conditions to obtain synthetic methods of other compounds.
In one embodiment of the present invention,
the compound of formula (II) can be prepared by the following reaction equation:
wherein R is 3 、R 4 、R 9 、R 10 、T 1 、D 1 N is as defined above.
More specifically, for example, in a preferred embodiment of the present invention, the compound of formula (II) may be prepared by the following reaction equation, but is not limited thereto:
wherein, the reaction condition A can be: etOAc (ethyl acetate), N-dimethylaniline, POCl 3 (phosphorus oxychloride); the reaction conditions B may be: DIPEA (N, N-diisopropylethylamine), DMSO (dimethyl sulfoxide).
In addition, in a preferred embodiment of the present invention,
In another preferred embodiment of the present invention,
the R is 3 And R is 4 Can be each independently selected from H, F, cl, br, I, OH, NH 2 CN, methyl and methoxy.
In another preferred embodiment of the present invention,
the R is 5 And R is 6 May each be independently selected from the group consisting of H, F, cl, br, I, OH and methyl.
In another preferred embodiment of the present invention,
the R is 5 And R is 6 Can be formed together with the carbon atoms to which they are commonly attached
In another preferred embodiment of the present invention,
In another preferred embodiment of the present invention,
the R is 8 Can be H or-C (=O) -CH 3 。
In another preferred embodiment of the present invention,
can be selected from the group consisting of Wherein R is a group consisting of 5 、R 6 、R 7 And R is 8 As defined above.
In another preferred embodiment of the present invention,
In another preferred embodiment of the present invention,
the palladium catalyst system may comprise Pd (dppf) Cl 2 ([ 1,1' -bis (diphenylphosphino) ferrocene]Palladium dichloride, K 2 CO 3 (Potassium carbonate), DIPEA (N, N-diisopropylbenzene)Phenylethylamine), 2-methyltetrahydrofuran and H 2 O。
In another preferred embodiment of the present invention,
the deprotection agent may comprise a solution of ethylenediamine and tetrabutylammonium fluoride (TBAF) in tetrahydrofuran.
In another preferred embodiment of the present invention,
the weight ratio of the compound of formula (II) to the compound of formula (III) may be 1:0.3-0.8 (e.g., 1:0.4, 1:0.45, 1:0.5, 1:0.53, 1:0.57, 1:0.6, or 1:0.7, etc.), preferably 1:0.5-0.6; and/or the weight ratio of the compound of formula (II) to the palladium catalyst in the palladium catalytic system may be 1:0.05-0.2 (e.g., 1:0.07, 1:0.08, 1:0.09, 1:0.1, 1:0.12, 1:0.15, 1:0.18, etc.), preferably 1:0.08-0.15.
In another preferred embodiment of the present invention,
the reaction may be carried out at a temperature of 60-100 ℃ (e.g., 65 ℃, 70 ℃, 75 ℃, 80 ℃, 85 ℃, 90 ℃, or 95 ℃, etc.), preferably 85-95 ℃ (e.g., 87 ℃, 90 ℃, or 92 ℃, etc.).
In another preferred embodiment of the present invention,
the method may further comprise a purification step of the compound of formula (I). The purification step may use various purification means common in the art, and may include, for example, rinsing, distillation, filtration, centrifugation, recrystallization, and the like, as long as the concentration of the compound of formula (I) in the product can be increased.
For the sake of brevity, the "compound of formula (I)" or "compound of the present application" described hereinafter may also encompass any isotopically-labeled compound of the compound of formula (I), or an optical isomer, geometric isomer, tautomer or mixture of isomers thereof, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof.
The term "optical isomer" means that when a compound has one or more chiral centers, each chiral center may exist in either the R configuration or the S configuration, and thus the various isomers constituted are optical isomers. Optical isomers include all diastereoisomers, enantiomers, meso, racemates or mixtures thereof. For example, the optical isomers may be separated by chiral chromatography columns or by chiral synthesis.
The term "geometric isomer" means that when a double bond is present in a compound, the compound may exist as cis, trans, E and Z isomers. Geometric isomers include cis, trans, E, Z, or mixtures thereof.
The term "tautomer" refers to an isomer that results from the rapid movement of an atom in a molecule at two positions. Those skilled in the art will appreciate that: tautomers can be transformed into each other, and in a certain state, an equilibrium state may be reached and coexist.
Unless otherwise indicated, references herein to "a compound of formula (I)" or "a compound of the invention" also encompass isotopically-labeled compounds in which any one of the atoms of the compound is replaced by an isotopic atom thereof. The present invention includes all pharmaceutically acceptable isotopically-labeled compounds of formula (I) wherein one or more atoms are replaced by an atom having the same atomic number as, but a different atomic mass or mass number than, an atom typically found in nature.
Examples of isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as 2 H (D) and 3 isotopes of H (T), carbon, such as 11 C、 13 C and C 14 Isotopes of C, chlorine, such as 35 Cl and Cl 37 Isotopes of Cl, fluorine, such as 18 Isotopes of F, iodine, such as 123 I and 125 isotopes of I, nitrogen, such as 13 N and 15 isotopes of N, oxygen, such as 15 O、 17 O and 18 isotopes of O, and sulfur, such as 35 S。
Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously used in a manner analogous to those described in the examples and preparations attached herein.
The compounds of formula (I) may exist in the form of pharmaceutically acceptable salts, for example, acid addition salts and/or base addition salts of the compounds of formula (I). As used herein, unless otherwise indicated, "pharmaceutically acceptable salts" include acid addition salts or base addition salts that may occur within the compounds of formula (I).
Pharmaceutically acceptable salts of the compounds of formula (I) include acid addition salts and base addition salts thereof. Suitable acid addition salts are formed from acids that form non-toxic salts. Examples include, but are not limited to: acetate, adipate, aspartate, benzoate, benzenesulfonate, bicarbonate/carbonate, bisulfate/sulfate, borate, camphorsulfonate, citrate, cyclohexylamine sulfonate, ethanedisulfonate, formate, fumarate, glucoheptonate, gluconate, glucuronate, hexafluorophosphate, 2- (4-hydroxybenzyl) benzoate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, 2-isethionate, lactate, malate, maleate, malonate, methanesulfonate, methylsulfate, napthalate, 2-naphthalenesulfonate, nicotinate, nitrate, orotate, oxalate, palmitate, phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate, glucarate, stearate, salicylate, tannate, tartrate, tosylate and trifluoroacetate. Suitable base addition salts are formed from bases which form non-toxic salts. Examples include, but are not limited to: aluminum, arginine, calcium, choline, diethylamine, diethanolamine, glycine, lysine, magnesium, meglumine, ethanolamine, potassium, sodium, tromethamine and zinc salts. Semi-salts of acids and bases, such as hemisulfate and hemicalcium salts, may also be formed. For a review of suitable salts, see Handbook of Pharmaceutical Salts:Properties, selection and Use by Stahl and Wermuth (Wiley-VCH, 2002). Methods for preparing pharmaceutically acceptable salts of the compounds described herein are known to those skilled in the art.
Certain compounds of the invention may exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the compounds of formula (I), whether in solvated form or unsolvated form, are encompassed within the scope of the present invention.
Certain compounds of the present invention may exist in different crystalline or amorphous forms, and, regardless of the form in which they exist, the compounds of formula (I) are included within the scope of the present invention.
To avoid ambiguity, definitions are given below for terms used herein. Unless otherwise indicated, the terms used herein have the following meanings.
The term "pharmaceutically acceptable" means that the corresponding compound, carrier or molecule is suitable for administration to a human. Preferably, the term refers to use with mammals, preferably humans, as certified by regulatory authorities such as any national regulatory agency of CFDA (china), EMEA (europe), FDA (united states), etc.
"prodrug" means a derivative which is converted into the compound of the present invention by a reaction with an enzyme, gastric acid or the like under physiological conditions in vivo, for example, by oxidation, reduction, hydrolysis or the like each carried out under the catalysis of an enzyme.
"metabolite" means all molecules derived from any of the compounds of the invention in a cell or organism, preferably a human.
As used herein, the term "substituted" means that one or more (preferably 1 to 5, more preferably 1 to 3) hydrogen atoms in the group are independently replaced by a corresponding number of substituents.
As used herein, the term "each independently" means that when the number of substituents exceeds one, the substituents may be the same or different.
As used herein, the term "optional" or "optionally" means that the event described may or may not occur. For example, a group "optionally substituted" means: the group may be unsubstituted or substituted.
As used herein, the term "alkyl" refers to saturated aliphatic hydrocarbons, including straight and branched chains. In some embodiments, the alkyl groups have 1 to 8, or 1 to 6,Or 1-3 carbon atoms. For example, the term "C 1-8 Alkyl "refers to a straight or branched chain radical having 1 to 8 carbon atoms. The term "C 1-8 Alkyl "includes the term" C "in its definition 1-6 Alkyl "," C 1 -C 3 Alkyl "and" C 1 -C 4 An alkyl group. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, 3-pentyl, isopentyl, neopentyl, (R) -2-methylbutyl, (S) -2-methylbutyl, 3-methylbutyl, 2, 3-dimethylpropyl, 2, 3-dimethylbutyl, hexyl, and the like. The alkyl group may be optionally substituted with one or more (e.g., 1 to 5) suitable substituents.
As used herein, the term "haloalkyl" refers to an alkyl group having one or more halogen substituents (up to perhaloalkyl, i.e., each hydrogen atom of the alkyl group is replaced with a halogen atom). For example, the term "C 1-6 Haloalkyl "means C having one or more halogen substituents 1-6 An alkyl group (up to perhaloalkyl, i.e., each hydrogen atom of the alkyl group is replaced with a halogen atom). As another example, the term "C 1-4 Haloalkyl "means C having one or more halogen substituents 1-4 An alkyl group (up to perhaloalkyl, i.e., each hydrogen atom of the alkyl group is replaced with a halogen atom); the term "C 1-3 Haloalkyl "means C having one or more halogen substituents 1-3 An alkyl group (up to perhaloalkyl, i.e., each hydrogen atom of the alkyl group is replaced with a halogen atom); and the term "C 1-2 Haloalkyl "means C having one or more halogen substituents 1-2 An alkyl group (i.e., methyl or ethyl) (up to perhaloalkyl, i.e., each hydrogen atom of the alkyl group is replaced with a halogen atom). As another example, the term "C 1 Haloalkyl "refers to a methyl group having 1, 2 or 3 halogen substituents. Examples of haloalkyl groups include: CF (compact flash) 3 、C 2 F 5 、CHF 2 、CH 2 F、CH 2 CF 3 、CH 2 Cl, and the like.
In this context, a range of numbers relating to the number of substituents, the number of carbon atoms, and the number of ring atoms represents a list of all integers within the range, and the range is merely a simplified representation. For example: "1-4 substituents" means 1, 2,3 or 4 substituents; "3-8 ring atoms" means 3, 4, 5, 6, 7 or 8 ring atoms. Accordingly, a range of numbers relating to the number of substituents, the number of carbon atoms, the number of ring atoms also encompasses any one of its subranges, and each subrange is also considered disclosed herein.
In a second aspect, the present application provides a pharmaceutical composition comprising a compound of formula (I) or an isotopically-labeled compound thereof, or an optical isomer, geometric isomer, tautomer or mixture of isomers, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof, and a pharmaceutically acceptable carrier.
The pharmaceutically acceptable carrier may be an organic or inorganic inert carrier material, for example, suitable carriers include water, gelatin, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols, petroleum jelly, mannitol, cellulose derivatives, sodium saccharin, glucose, sucrose, magnesium carbonate, saline, glycerol, ethanol, and the like. In addition, the pharmaceutical composition may contain other pharmaceutical additives such as flavoring agents, preservatives, stabilizers, emulsifiers, buffers, diluents, binders, wetting agents, disintegrants, lubricants, glidants and the like.
The dosage form of the pharmaceutical composition of the present application may be a liquid dosage form, a solid dosage form or a semi-solid dosage form. The liquid preparation can be solution (including true solution and colloid solution), emulsion (including o/w type, w/o type and multiple emulsion), suspension, injection (including injection solution, powder injection and transfusion), eye drop, nasal drop, lotion, liniment, etc.; the solid dosage forms can be tablets (including common tablets, enteric coated tablets, buccal tablets, dispersible tablets, chewable tablets, effervescent tablets, orally disintegrating tablets), capsules (including hard capsules, soft capsules, enteric coated capsules), granules, powders, pills, suppositories, films, patches, aerosols, sprays and the like; the semisolid dosage form may be an ointment, gel, paste, or the like. The pharmaceutical composition of the present application can be formulated as a general formulation, as well as a sustained release formulation, a controlled release formulation, a targeted formulation, and various microparticle delivery systems.
In some embodiments, the dosage form of the pharmaceutical composition is selected from the group consisting of tablets, granules, powders, syrups, inhalants and injections.
Solid dosage forms for oral administration may include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert excipient (or carrier) (e.g., sodium citrate or dicalcium phosphate), which may further include: (a) Fillers or admixtures (e.g., starch, lactose, sucrose, glucose, mannitol, and silicic acid); (b) Binders (e.g., carboxymethyl cellulose, alginates, gels, polyvinyl pyrrolidone, sucrose, and gum arabic); (c) humectants (e.g., glycerol); (d) Disintegrants (e.g., agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain synthetic silicates, sodium carbonate); (e) a solution retarder (e.g., paraffin); (f) an absorption enhancer (e.g., a quaternary ammonium compound); (g) Wetting agents (e.g., cetyl alcohol and glycerol monostearate); (h) Adsorbents (e.g., kaolin and bentonite) and (i) lubricants (e.g., talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate) or mixtures thereof.
Formulations suitable for parenteral administration, such as injection, may include aqueous and non-aqueous isotonic sterile solutions suitable for injection, and aqueous and non-aqueous sterile suspensions. The parenteral formulations provided herein are optionally contained in unit-dose or multi-dose sealed containers (e.g., ampoules) and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of a sterile liquid carrier (e.g., water for injection) immediately prior to use. Examples of suitable diluents for reconstitution of the pharmaceutical composition (e.g., prior to injection) include bacteriostatic water for injection, 5% dextrose in water, phosphate buffered saline, ringer's solution, saline, sterile water, deionized water, and combinations thereof.
Sprays can contain excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. The spray may additionally contain conventional propellants such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons such as butane and propane. The inhalants may comprise excipients such as lactose, or aqueous solutions comprising, for example, polyethylene oxide-9-lauryl ether, glycocholate and deoxycholate, or oily solutions for administration as nasal drops or sprays, or as gels.
The content of the compound of the present application in the pharmaceutical composition thereof may be adjusted according to actual needs (e.g., dosage form, mode of administration, administration subject, etc.), for example, 0.1 to 95% by weight, for example, 1 to 95% by weight, 5 to 90% by weight, 10 to 80% by weight, etc.
In particular, 0.01 to 10g (e.g., 0.05g, 0.1g, 0.5g, 1g, 5g, etc.) of a compound of the present application may be specifically included in a pharmaceutical composition of the present application.
In a third aspect, the present application provides the use of a compound of formula (I) or an isotopically-labeled compound thereof, or an optical isomer, geometric isomer, tautomer or mixture of isomers, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof, in the manufacture of a medicament for treating or preventing a disease or condition mediated by Syk and VEGFR2 in a subject in need thereof as a dual-target inhibitor of Syk and VEGFR 2. The compounds of formula (I) or isotopically-labeled compounds thereof, or optical isomers, geometric isomers, tautomers or mixtures of isomers thereof, or pharmaceutically acceptable salts thereof, or prodrugs thereof, or metabolites thereof, may be used for treating or preventing diseases or disorders mediated by Syk and VEGFR2 in a subject in need thereof.
The term "subject" as used herein refers to any human or non-human organism that can potentially benefit from treatment with a compound of formula (I). Exemplary subjects include humans or mammals of any age. Preferably, the subject is a human.
The term "treating" as used herein includes treating a disease or condition in a mammal, particularly a human, and includes: (a) Inhibiting an infection, disease or condition, i.e., inhibiting or delaying the progression of an infection, disease or condition; (b) Remit an infection, disease or condition, i.e., cause regression of the disease or condition, and/or (c) cure of the infection, disease or condition.
The term "prophylaxis" as used herein includes prophylactic treatment in mammals, particularly humans, to reduce the likelihood of an infection, disease or condition occurring. Patients receiving prophylactic therapy may be selected based on the increased risk of infection or suffering from a disease or disorder as compared to the general population. "preventing" may include treating a subject who has not yet presented with an infection or clinical condition, and preventing a second occurrence of the same or a similar infection or clinical condition.
In some embodiments, the disease or disorder mediated by Syk and VEGFR2 may be selected from allergic, autoimmune and inflammatory diseases, such as dry eye and allergic conjunctivitis, retinal inflammatory diseases, age-related macular degeneration (AMD), proliferative Diabetic Retinopathy (PDR) and retinopathy of prematurity (ROP), rheumatoid arthritis, glomerulonephritis, multiple vasculitis, idiopathic Thrombocytopenic Purpura (ITP), myasthenia gravis, allergic rhinitis, chronic Obstructive Pulmonary Disease (COPD), adult respiratory distress syndrome (ARD), and asthma. In other embodiments, the disease or disorder is cancer.
In some embodiments, the compounds of the invention may be administered by oral, parenteral, intravenous, intramuscular, subcutaneous, nasal, oral mucosal, ocular, pulmonary, respiratory, vaginal, rectal, intraperitoneal, intralesional, perilesional, and the like routes.
By "therapeutically effective amount" is meant an amount of a compound of the present application that, when administered alone or in combination, treats or prevents a disease or disorder mediated by Syk and VEGFR 2.
The particular dosage administered will depend on the route of administration, the severity of the disease, the age and weight of the patient, and other factors typically considered by the attending physician in determining the individual regimen and dosage level best suited for a particular patient. For example, the daily dose of a compound of the present application may be, in particular, 0.001-150mg/kg body weight (e.g., 0.1mg/kg body weight, 1mg/kg body weight, 10mg/kg body weight, 100mg/kg body weight, etc.).
The specific frequency of administration may be determined by one of skill in the relevant art, for example, 1 day 1, 2 days 1, 3 days 1, 4 days 1, 5 days 1, 6 days 1,1 day 2, 1 day 3, etc.
Those skilled in the art will appreciate that the definitions and preferences described in one aspect of the present application apply equally to other aspects. It will be apparent to those skilled in the art that the embodiments of the various aspects of the present application may be combined in various ways without departing from the subject matter and concepts of the application, and such combinations are also included within the scope of the application.
Detailed Description
The invention is further illustrated by the following examples; but these examples do not limit the scope of the invention. All reactants used in each example were obtained commercially unless otherwise stated; the instruments and equipment used in the synthesis experiments and the product analysis and detection are all conventional instruments and equipment commonly used in organic synthesis.
Examples
The synthetic route is as follows:
1) Preparation of Compounds 2-3
The raw materials and the amounts of the raw materials in step 1 are shown in Table 1 below.
TABLE 1
To a 50L reactor, 11.0L dimethyl sulfoxide was added, stirring was started at 150rpm, and the temperature was shown to be an internal temperature of 20 ℃. 833.0g of Compound 2-2, 1510.0g of N, N-diisopropylethylamine and 1100.0g of Compound 2-1 were added in this order. Setting the external temperature to be 100 ℃ and stirring for 24 hours at the internal temperature of 95-100 ℃.
The reaction was checked by HPLC, which showed less than 3% of compound 2-1 remaining. The heating was turned off and the reaction solution was cooled to 20 to 25 ℃. The reaction solution was slowly poured into 30.0L of stirred water. The internal temperature is controlled to be 10-15 ℃, and the stirring is carried out for 0.5 hour, and the rotating speed is 100rpm. And (3) maintaining the internal temperature at 10-15 ℃, carrying out vacuum filtration, collecting a filter cake, putting the filter cake into a reaction kettle again, and adding 15.0L of isopropanol into the kettle. Setting the external temperature at 85 ℃ and stirring for 1 hour at the internal temperature of 80-85 ℃. And (3) carrying out reduced pressure suction filtration under the condition of keeping the internal temperature at 80-85 ℃, and washing the filter cake with 4.0L of isopropanol. The filter cake is collected and placed in a vacuum drying oven, and vacuum drying is carried out for 12 hours under the conditions of 50-55 ℃ and minus 0.1Mpa, thus 1300.0g of compound 2-3 is obtained, and the yield is 79.0%.
2) Preparation of Compounds 2-5
The raw materials and the amounts of the raw materials in step 2 are shown in Table 2 below.
TABLE 2
8.0L of 2-methyltetrahydrofuran is added into a 50L reaction kettle, stirring is started, the rotating speed is 150rpm, and the external temperature is set to be 5-10 ℃. 1070.0g of Compound 2-4, 764.0g of potassium carbonate and 711.7g of N, N-diisopropylethylamine were added in this order. 1200.0g of 2-chloromethoxyethyl trimethylsilicon is added dropwise by a constant pressure dropping funnel at an internal temperature of 5-10 ℃, and the mixture is stirred for 3 hours under the condition that the internal temperature is controlled to be 15-20 ℃ after the completion of the dropwise addition.
The reaction solution is taken for HPLC detection, and the spectrogram shows that the residual content of the compound 2-4 is less than 1.0 percent. The reaction vessel was continuously charged with 7.2L2-methyltetrahydrofuran, 3.8L of water, 1900.0g of Compound 2-3, 1376.0g of Potassium carbonate and 164.0g of Pd (dppf) Cl 2 . Nitrogen was introduced into the reaction vessel to displace for 20 minutes, and the external temperature was set at 85 ℃. Stirring at 80-85 deg.c for 16 hr. Sampling HPLC detects that the compound 2-3 has been completely converted, cooling to an internal temperature of 15-20 ℃, and slowly adding 10.0L of water and 40.0L of n-heptane into the reaction kettle under stirring. Stirring at 15-20 deg.C for 20 min, vacuum filtering, vacuum drying the filter cake in vacuum drying oven at 50-55 deg.C and-0.1 MPa for 20 hr2800.0g of crude compound 2-5 were obtained.
28.0L2-methyltetrahydrofuran was added to a 50L reaction vessel, and 2800.0g of crude compound 2-3 was added with stirring. Heating is started, the external temperature is set to be 75-80 ℃, after stirring for 1 hour, the crude compound 2-3 is completely dissolved, then 820.0g CPL type active carbon is added, and stirring is carried out for 16 hours at the internal temperature of 75-80 ℃. Filtering the mixture at the temperature of 70-80 ℃ through a diatomite layer with the thickness of 2-4 cm while the mixture is hot, and collecting filtrate.
The collected filtrate was poured back into the reaction vessel again, and 560.0g of CPL activated carbon was continuously added. Stirring for 16 hours at the internal temperature of 75-80 ℃. Filtering through a diatomite layer with the thickness of 2-4 cm at the temperature of 70-80 ℃ while the diatomite layer is hot, collecting filtrate, concentrating under reduced pressure at the temperature of 40-45 ℃ and the pressure of minus 0.1MPa until the total volume of the filtrate is about 15 liters, pouring the filtrate back into a reaction kettle again, adding 30.0L of n-heptane in batches, stirring for 1 hour at the temperature of 15-20 ℃, decompressing and filtering to obtain a filter cake, and vacuum drying (40-50 ℃ and the pressure of minus 0.1 MPa) the filter cake for 20 hours to constant weight to obtain 1650.0g of compound 2-3, wherein the yield is 68.0%.
3) Preparation of Compounds 2-6
The raw materials and the amounts of the raw materials in step 3 are shown in Table 3 below.
TABLE 3 Table 3
To a 50L reactor was added 20.0L of 1mol/L TBAF tetrahydrofuran solution, and stirring was started at 150rpm. 2000.0g of Compound 2-3 and 222.0g of ethylenediamine were added in this order. Stirring for 16 hours at the internal temperature of 65-72 ℃.
Taking the reaction liquid for HPLC detection, wherein the spectrogram shows that the residual content of the compound 2-3 is less than 1%, and 16.0L tetrahydrofuran is added into a reaction kettle under the condition that the temperature is kept between 50 and 55 ℃, the internal temperature is controlled between 39 and 42 ℃ and stirred for 2 hours, and then the stirring is continued for 2 hours at 15 to 20 ℃. Vacuum filtering, pouring the filter cake back into the kettle again, adding 25.0L of water and 12.5L of ethanol, and stirring for 16 hours at the internal temperature of 65-70 ℃. Vacuum heat filtering at 65-70 deg.c, collecting filter cake, vacuum drying at 50-55 deg.c and-0.1 MPa for 12 hr to constant weight to obtain 1270.3g compound 2-6 crude product with yield of 84.0%.
4) Purification of Compounds 2-6
The raw materials and the amounts of the raw materials in step 4 are shown in Table 4 below.
TABLE 4 Table 4
To a 50L reactor was added 15.0L ethanol and 25.0L deionized water, and 1200.0g crude compound 2-6 was added in portions. The external temperature is set to be 72 ℃, and the stirring is carried out for 48 hours at the internal temperature of 65-72 ℃.
Maintaining the internal temperature at 65-72 ℃, filtering while the mixture is hot under reduced pressure, collecting a filter cake, pouring the filter cake back into the reaction kettle again, and adding 40.0L of deionized water into the kettle. The internal temperature is controlled to be 65-75 ℃ and stirred for 16 hours. Vacuum filtering at 65-75deg.C, vacuum drying (40-50deg.C, -0.1 MPa) for 20 hr to constant weight to obtain 1140.0g compound 2-6 with yield of 95.0%.
Claims (19)
1. A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof,
wherein,,
R 1 and R is 2 One of which is H and the other of which is pyrazolyl;
R 3 and R is 4 Each independently selected from the group consisting of H, F, cl, br, I, OH, NH 2 、CN、C 1-3 Alkyl and C 1-3 Alkoxy group, said C 1-3 Alkyl and C 1-3 Alkoxy is optionally substituted with 1, 2 or 3 halogens;
T 1 CH or N;
R 5 and R is 6 Each independently selected from the group consisting of H, F, cl, br, I, OH and C 1-3 Alkyl group, said C 1-3 Alkyl is optionally substituted with 1, 2 or 3 halogens; alternatively, R 5 And R is 6 Together with the carbon atoms to which they are attached form an oxetanyl group;
R 8 is H or-C (=O) -C 1-3 An alkyl group; and
n is 1 or 2; and is also provided with
Wherein the method comprises the steps of:
under the reaction condition of existence of palladium catalytic system and SEM-Cl, wherein the palladium catalytic system comprises 2-methyltetrahydrofuran and H 2 O, reacting a compound of formula (II):
wherein,,
R 9 and R is 10 One of which is H and the other is halogen;
with a compound of formula (III):
the reaction is carried out,
and after the reaction is finished, adding a deprotection agent into a reaction system to remove a protected SEM group so as to obtain the compound of the formula (I).
3. The method of claim 1, wherein the R 3 And R is 4 Each independently selected from the group consisting of H, F, cl, br, I, OH, NH 2 CN, methyl and methoxy.
4. The method of claim 1, wherein the R 5 And R is 6 Each independently selected from the group consisting of H, F, cl, br, I, OH and methyl.
7. The method of claim 1, wherein the R 8 Is H or-C (=O) -CH 3 。
10. The process of any one of claims 1-9, wherein the palladium catalytic system further comprises Pd (dppf) Cl 2 、K 2 CO 3 And DIPEA.
11. The method of any of claims 1-9, wherein the deprotection agent comprises a solution of ethylenediamine and tetrabutylammonium fluoride in tetrahydrofuran.
12. The method of any one of claims 1-9, wherein the weight ratio of the compound of formula (II) to the compound of formula (III) is 1:0.3-0.8; and/or the weight ratio of the compound of formula (II) to the palladium catalyst in the palladium catalytic system is 1:0.05-0.2.
13. The method of claim 12, wherein the weight ratio of the compound of formula (II) to the compound of formula (III) is 1:0.5-0.6.
14. The process of claim 12, wherein the weight ratio of the compound of formula (II) to the palladium catalyst in the palladium catalytic system is 1:0.08-0.15.
15. The process according to any one of claims 1-9, wherein the reaction is carried out at a temperature of 60-100 ℃.
16. The method of claim 15, wherein the reaction is performed at a temperature of 85-95 ℃.
17. The process according to any one of claims 1-9, wherein the process further comprises a step of purifying the compound of formula (I).
19. The process of claim 18, wherein the reaction conditions of step 1 comprise EtOAc, N-dimethylaniline and POCl 3 The method comprises the steps of carrying out a first treatment on the surface of the And reaction conditions B of step 2 include DIPEA and DMSO.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210343193.5A CN114591338B (en) | 2022-03-31 | 2022-03-31 | Preparation method and application of Syk and VEGFR2 double-target inhibitor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210343193.5A CN114591338B (en) | 2022-03-31 | 2022-03-31 | Preparation method and application of Syk and VEGFR2 double-target inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114591338A CN114591338A (en) | 2022-06-07 |
CN114591338B true CN114591338B (en) | 2023-05-09 |
Family
ID=81821165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210343193.5A Active CN114591338B (en) | 2022-03-31 | 2022-03-31 | Preparation method and application of Syk and VEGFR2 double-target inhibitor |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114591338B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220130747A (en) * | 2020-02-24 | 2022-09-27 | 오큐멘션 테라퓨틱스 (수저우) 씨오., 엘티디. | 1H-pyrazole derivatives and uses as Syk and VEGFR2 dual target inhibitors |
CN116554177B (en) * | 2023-04-24 | 2024-02-27 | 苏州欧康维视生物科技有限公司 | Salt form and crystal form of nitrogen-containing heterocyclic compound and application of salt form and crystal form |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101044138A (en) * | 2004-11-02 | 2007-09-26 | 辉瑞有限公司 | Methods for preparing indazole compounds |
CN108290860A (en) * | 2015-11-25 | 2018-07-17 | Ucb生物制药私人有限公司 | Imino group tetrahydropyrimidine ketone derivatives as PLASMEPSIN V inhibitor |
WO2018144605A1 (en) * | 2017-02-02 | 2018-08-09 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
AU2020102849A4 (en) * | 2020-10-19 | 2020-12-17 | Guangdong University Of Technology | Method for directly synthesizing N, N'-dialkyl urea and derivatives thereof by using one-step visible-light CO2 catalysis method |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6709792B2 (en) * | 2015-01-29 | 2020-06-17 | ジェネンテック, インコーポレイテッド | Therapeutic compounds and uses thereof |
SG11201708190UA (en) * | 2015-04-29 | 2017-11-29 | Janssen Pharmaceutica Nv | Azabenzimidazoles and their use as ampa receptor modulators |
JOP20190156B1 (en) * | 2016-12-23 | 2023-09-17 | Bayer Pharma AG | Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor |
CN111320633B (en) * | 2018-12-14 | 2022-09-27 | 中国医药研究开发中心有限公司 | Pyrrole/imidazo six-membered heteroaromatic ring compound and preparation method and medical application thereof |
US20220372042A1 (en) * | 2019-10-03 | 2022-11-24 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
KR20220130747A (en) * | 2020-02-24 | 2022-09-27 | 오큐멘션 테라퓨틱스 (수저우) 씨오., 엘티디. | 1H-pyrazole derivatives and uses as Syk and VEGFR2 dual target inhibitors |
-
2022
- 2022-03-31 CN CN202210343193.5A patent/CN114591338B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101044138A (en) * | 2004-11-02 | 2007-09-26 | 辉瑞有限公司 | Methods for preparing indazole compounds |
CN108290860A (en) * | 2015-11-25 | 2018-07-17 | Ucb生物制药私人有限公司 | Imino group tetrahydropyrimidine ketone derivatives as PLASMEPSIN V inhibitor |
WO2018144605A1 (en) * | 2017-02-02 | 2018-08-09 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
AU2020102849A4 (en) * | 2020-10-19 | 2020-12-17 | Guangdong University Of Technology | Method for directly synthesizing N, N'-dialkyl urea and derivatives thereof by using one-step visible-light CO2 catalysis method |
Also Published As
Publication number | Publication date |
---|---|
CN114591338A (en) | 2022-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230117605A1 (en) | Dosage forms and regimens for amino acid compounds | |
CN114591338B (en) | Preparation method and application of Syk and VEGFR2 double-target inhibitor | |
US10793564B2 (en) | Amino acid compounds and methods of use | |
TWI476190B (en) | Hepatitis c virus inhibitors | |
US8138215B2 (en) | Hepatitis C virus inhibitors | |
US20230181546A1 (en) | Treatment of respiratory diseases with amino acid compounds | |
US12024524B2 (en) | Imidazopyridazines as modulators of IL-17 | |
TW201038559A (en) | Hepatitis C virus inhibitors | |
TW201040160A (en) | Hepatitis C virus inhibitors | |
CN113784963B (en) | Compounds useful as RET kinase inhibitors and uses thereof | |
TW201121955A (en) | Hepatitis C virus inhibitors | |
JP7187575B2 (en) | Benzopyrazole compounds as RHO kinase inhibitors | |
CN114621232B (en) | Preparation method and application of Syk and VEGFR2 double-target-point inhibitor | |
CA2826774A1 (en) | Hepatitis c virus inhibitors | |
DK2951159T3 (en) | CRYSTALLIC FORMS OF {[1-CYANO-5- (4-CHLORPHENOXY) -4-HYDROXY-ISOQUINOLIN-3-CARBONYL] -AMINO} ACETIC ACID | |
CA2988468A1 (en) | A 7-substituted-1-aryl-naphthyridin-3-carboxylic acid amide and its use as a positive allosteric modulator of the muscarinic m2 receptor | |
EP3348547B1 (en) | Benzimidazole derivatives as nav 1.7 (sodium channel, voltage-gated, type ix, alpha subunit (scn9a)) inhibitors for treating pain, dysuria and multiple sclerosis | |
WO2023033098A1 (en) | Bicyclic nitrogen-containing heterocyclic derivative having virus growth inhibitory activity and pharmaceutical composition containing same | |
WO2022228576A1 (en) | Protein regulator-targeted compound and application thereof | |
CN111434662A (en) | Haloallylamine compound and application thereof | |
US20230028658A1 (en) | Expanded dosage regimens for integrin inhibitors | |
EP4361163A1 (en) | Protein inhibitor or degrading agent, pharmaceutical composition containing same and pharmaceutical use | |
CA3121139A1 (en) | Pyrazoles as modulators of hemoglobin | |
US20080188517A1 (en) | Crystalline forms of a factor xa inhibitor | |
JP2024508329A (en) | Synthetic methods and intermediates for producing compounds for treating KIT- and PDGFRA-mediated diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |